IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 124 filers reported holding IMMUNOVANT INC in Q3 2021. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,454,004 | +102.8% | 63,923 | +0.2% | 0.00% | +100.0% |
| Q2 2023 | $1,210,134 | +54.3% | 63,792 | +26.1% | 0.00% | +100.0% |
| Q1 2023 | $784,372 | -14.0% | 50,572 | -1.6% | 0.00% | 0.0% |
| Q4 2022 | $911,906 | +221.1% | 51,375 | +1.0% | 0.00% | – |
| Q3 2022 | $284,000 | +43.4% | 50,863 | +0.0% | 0.00% | – |
| Q2 2022 | $198,000 | -30.0% | 50,856 | -1.1% | 0.00% | – |
| Q1 2022 | $283,000 | -39.9% | 51,445 | -7.0% | 0.00% | -100.0% |
| Q4 2021 | $471,000 | +7.5% | 55,335 | +9.8% | 0.00% | 0.0% |
| Q3 2021 | $438,000 | -19.8% | 50,396 | -2.5% | 0.00% | 0.0% |
| Q2 2021 | $546,000 | -39.8% | 51,695 | -8.6% | 0.00% | 0.0% |
| Q1 2021 | $907,000 | -65.5% | 56,540 | -0.7% | 0.00% | -75.0% |
| Q4 2020 | $2,629,000 | +41.4% | 56,915 | +7.7% | 0.00% | +33.3% |
| Q3 2020 | $1,859,000 | +164.8% | 52,832 | +83.4% | 0.00% | +200.0% |
| Q2 2020 | $702,000 | – | 28,814 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |